Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
2/2018
vol. 120 abstract:
Review paper
The position of biologic therapies in the treatment of non-infectious uveitis. Part II
Maja Waszczyk-Łączak
,
Jacek P. Szaflik
Online publish date: 2018/10/25
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Non-infectious uveitis is a heterogeneous group of diseases, which share a common denominator, that is, the inflammation within the structure of the eye. The goal of treatment in non-infectious uveitis is to inhibit the abnormal immune response. Glucocorticoids are still the basic therapy followed by immunosuppressants should there be no response to the first line treatment. Systemic biologic agents are another alternative. Biological therapy involves the administration of substances intended to bind to the specific molecules which trigger the inflammatory response. Biologic agents are defined as bioengineered receptor complexes, antibodies, Fab fragments, and agents such as interferons that affect the expression of pro-and anti-inflammatory components of the immune system. In the article, the drugs, which inhibit interleukin-6, interleukin-1, interleukin-2 as well as anti-CD20 immunoglobulins and interferons will be discussed.
keywords:
interleukins, biological therapy, non-infectious uveitis, anti-CD20 antibody, interferons |
|